Take Homes in Benign Hematology

Take Homes in Benign Hematology

Source:

Healio Interview

Disclosures: Heeney reports consulting for AstraZeneca, Cyclerion Therapeutics, Inc., Forma Therapeutics, Inc., Global Blood Therapeutics, Inc., Micelle BioPharma, Novartis Pharmaceuticals Corporation, Pfizer, and Vertex Pharmaceuticals, Inc./CRISPR Therapeutics; and receiving grant or research support from AstraZeneca, Global Blood Therapeutics and Novartis Pharmaceuticals Corporation.
December 20, 2021
1 min watch
Save

VIDEO: ‘Interesting’ real-world data on sickle cell treatment from ASH

Source:

Healio Interview

Disclosures: Heeney reports consulting for AstraZeneca, Cyclerion Therapeutics, Inc., Forma Therapeutics, Inc., Global Blood Therapeutics, Inc., Micelle BioPharma, Novartis Pharmaceuticals Corporation, Pfizer, and Vertex Pharmaceuticals, Inc./CRISPR Therapeutics; and receiving grant or research support from AstraZeneca, Global Blood Therapeutics and Novartis Pharmaceuticals Corporation.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Matthew M. Heeney, MD, highlighted “interesting” real-world and long-term follow-up studies for the treatment of sickle cell that were presented at ASH Annual Meeting and Exposition.

“They’re gradually moving out to the phase 2/3, sort of more pivotal, trial range,” Heeney, associate chief of hematology and director of the Sickle Cell Program at Dana-Farber/Boston Children’s Cancer and Blood Disorder Center and associate professor at Harvard Medical School, said.